BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,056 filers reported holding BAXTER INTL INC in Q1 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $77,000 | +4.1% | 1,000 | 0.0% | 0.02% | 0.0% |
| Q2 2018 | $74,000 | -99.1% | 1,000 | -99.2% | 0.02% | -99.1% |
| Q1 2018 | $8,025,000 | -2.6% | 123,387 | -3.1% | 2.17% | -3.3% |
| Q4 2017 | $8,235,000 | -0.7% | 127,395 | -3.7% | 2.24% | -3.8% |
| Q3 2017 | $8,297,000 | -1.1% | 132,229 | -4.6% | 2.33% | -5.1% |
| Q2 2017 | $8,391,000 | +8.8% | 138,601 | -6.8% | 2.45% | +8.3% |
| Q1 2017 | $7,715,000 | +15.4% | 148,765 | -1.3% | 2.26% | +12.3% |
| Q4 2016 | $6,684,000 | -5.7% | 150,755 | -0.1% | 2.02% | -10.2% |
| Q3 2016 | $7,091,000 | +0.9% | 150,932 | -2.8% | 2.25% | -2.8% |
| Q2 2016 | $7,025,000 | +8.3% | 155,343 | -1.6% | 2.31% | +6.7% |
| Q1 2016 | $6,485,000 | +111.4% | 157,863 | +96.3% | 2.16% | +102.3% |
| Q4 2015 | $3,068,000 | +15.9% | 80,430 | -0.2% | 1.07% | +10.2% |
| Q3 2015 | $2,646,000 | -53.4% | 80,554 | -0.8% | 0.97% | -48.2% |
| Q2 2015 | $5,679,000 | +3.2% | 81,209 | +1.1% | 1.88% | +0.7% |
| Q1 2015 | $5,503,000 | -3.6% | 80,343 | +3.1% | 1.86% | -4.1% |
| Q4 2014 | $5,710,000 | – | 77,909 | – | 1.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |